Desmoid Tumors Market Research Report- Forecast till 2030

Desmoid Tumors Market Research Report Information: Diagnosis (Biopsy, Electron Microscopy, Immunohistochemical Analysis), Treatment (Surgery, Radiation, Chemotherapy, Medication, Hormone, Molecular Targeted Therapy), End User - Forecast till 2030

ID: MRFR/Pharma/3431-HCR | | Region: Global | 85 Pages         

Desmoid Tumors Market Speak to Analyst Request a Free Sample

Desmoid Tumors Market Overview

The Desmoid Tumors Market is projected to reach USD 4,408 Million by 2030 at 5.1% CAGR during the forecast period 2022-2030. The demand for effective and sophisticated chemotherapeutic drugs has grown, as cancer cases have increased worldwide. During the forecast period, this demand will have a favorable impact on the desmoid tumors market.

Desmoid fibromatosis is another name for desmoid tumors. These benign tumors are quite uncommon in the general public. They are fibrous tumors that grow in the body's fibrous tissue, most typically in the arms, legs, or abdomen, but they can also occur in the head and neck. Several non-invasive procedures for detecting desmoid tumors, including ultrasound, MRI scan, and CT scans. The true diagnosis of this tumor can only be made once a competent pathologist examines a small bit of cancer.

A painless swelling or lump, pain and obstruction of the bowels, limping, pain caused by squeezed nerves or muscles, and other symptoms are signs of desmoid tumors. Anti-inflammatory medications, Chemotherapy, hormone therapy, and surgery are among the most popular treatment choices for desmoid tumors. Angiogenesis inhibitors and chemotherapy drugs are among the new medicines being researched. The rising prevalence of cancer cases among the global population is expected to fuel the desmoid tumors market growth.

Covid-19 Analysis

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The desmoid fibromatosis market saw a slight downfall post the pandemic due to the lockdown and physical distancing.

However, the key companies have adopted measures to expand the distribution of desmoid treatment and diagnosis equipment across the globe. Moreover, people are growing aware of desmoid tumors, and the price of pharmaceutical products is increasing. Hence, these factors are expected to boost the desmoid tumors market value in the years to come.

Market Dynamics 


A few factors may drive the growth of the desmoid tumors market share. Due to rising demand for efficient chemotherapeutic agents, high unmet needs of present treatment, and increased research and development expenditures in the healthcare sector, the desmoid fibromatosis market is likely to grow soon.


The major key companies of the market are adopting various trends such as new product launches with advanced technology for diagnosis and treatment. Many developed countries' governments have raised financing to research novel medicines for desmoid tumors, which is moving the tumor market forward. Major players in the market are investing in research and development efforts worldwide, which could contribute to further market expansion.


There are a few factors that may inhibit the desmoid tumors market growth. One of the most important of them is the high cost of the procedures. Desmoid tumors and related illnesses have a high treatment and management cost. The lack of infrastructure in the healthcare sectors of low and middle-income countries may also hinder the market growth in the long run.


There are various concerns with the market that may challenge the key players of the market. This includes the cost of the diagnosis and treatment solutions. High treatment and maintenance costs for desmoid tumors and related illnesses and a lack of infrastructure in medium and low-income nations may limit the expansion of the desmoid tumors market forecast.

Cumulative Growth Analysis

The desmoid tumors market is anticipated to grow at a substantial speed in the years to come. The desmoid fibromatosis market value is expected to grow at a CAGR of about 4.5%. The demand for effective and sophisticated chemotherapeutic drugs has grown, as cancer cases have increased worldwide. During the forecast period, this demand will have a favorable impact on the market.

Value Chain Analysis

The need for effective and sophisticated chemotherapeutic drugs has grown as cancer cases have increased around the globe. During the forecast period, this requirement will have a positive effect on the desmoid tumors market. Furthermore, governments in several developed countries have increased investment in innovative medicines to treat desmoid tumors, driving the market further. 

Major players of the market are investing in the research and development of their treatment & diagnosis worldwide, which could contribute to further market expansion. Unfortunately, the increased cost of managing and treating desmoid tumors, as well as the lack of advanced healthcare infrastructure in middle-income and low-income countries, may limit the market's expansion. 

Segment Overview

The desmoid tumors market is classified into many segments such as diagnosis, treatment, and end-user. Listed below are the desmoid fibromatosis market segments:

By Diagnosis

  • ¬†Immunohistochemical Analysis

  • ¬†Biopsy¬†

  • ¬†Electron microscopic examination

  • ¬†Others¬†

By Treatment

  • ¬†Novel molecular-targeted Therapy

    • Sorafenib based Therapy

    • Gleevec based Therapy

  • ¬†Surgery¬†

  • ¬†Chemotherapy¬†

  • ¬†Radiation therapy¬†

  • ¬†Hormone therapy¬†

  • ¬†Anti-Inflammatory Medication

  • ¬†Others¬†

By End-user

  • ¬†Hospitals & clinics

  • ¬†Others¬†

Regional Analysis

The regional division of the desmoid tumors market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. The Americas will dominate the market in the forecast years because of increased public awareness and rising health expenditures. According to the Centers for Disease Control and Prevention (CDC), individuals with chronic health issues account for 86% of the yearly healthcare expenditure.

Furthermore, the growing involvement of major players and new marketers in the evolution of treatment approaches has gotten a lot of attention. In the market of desmoid tumors, Europe is ranked second. The market in Europe is projected to be driven by government assistance for research and development and improvements in reimbursement policies in the healthcare sector.

Due to the large patient pool and expanding healthcare technologies, Asia Pacific is projected to be the fastest-growing desmoid tumors market. Due to the lack of technical understanding and inadequate healthcare facilities, the Middle East and Africa have the smallest need for desmoid tumors.

Competitive Landscape 

The desmoid tumors industry is dominated by a few companies that play a vital role in the market growth. These tumor diagnosis and treatment provider companies are called key companies of the market. They contribute to the largest share of the market profit.

The companies account for the market profits by adopting various desmoid tumors market trends such as joint ventures, product launches, company expansions, and procurements. They provide innovative solutions for patients suffering from desmoid tumors.

Key Players

Below are the key companies that offer desmoid tumor diagnosis and treatment solutions in the global market:

  • Debiopharm Group

  • Novartis AG

  • Bayer AG

  • Beckman Coulter Inc.

  • Amgen Inc.

  • F. Hoffmann-La Roche Ltd

  • Stryker Corporation

  • Abbott Laboratories

  • AbbVie Inc.

  • Others¬†

Recent Developments 

  • Desmoid tumors may be treated effectively with new hormone treatments. Because estrogen may have a role in desmoid tumors, one study is looking into using endoxifen (Z-Endoxifen HCl) to treat tumors that haven't responded to other hormone therapy. Other estrogen-linked malignancies have been proven to be slowed or stopped by this innovative Therapy.

  • High-frequency ultrasound is a new non-invasive treatment that uses focused ultrasound beams to target and eliminate a desmoid tumor without hurting adjacent tissues. In some cases, it may be a viable alternative to surgery. Though high-frequency ultrasound is used to treat desmoid tumors in very few medical facilities, clinical trial research into its efficacy and long-term implications are only being started.

Report Overview

This report delivers all the information about the desmoid tumors market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected market outlook.


  • Europe

  • Asia-Pacific

  • North America

  • Middle East & Africa

  • Rest of the world

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   5.10% (2020-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others
  Key Market Opportunities

  • Rising demand of effective chemotherapeutic agents
  • High unmet needs of current treatment
  • Increase in research and development expenditure
  •   Key Market Drivers

  • High cost of treatment & management of desmoid tumors and related disorders
  • Lack of infrastructure

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The desmoid tumors market CAGR would be 5.1% during the forecast period.

    The desmoid tumor market restraints would be high cost of treatment and lack of infrastructure.

    End users mentioned in the desmoid tumor market report are hospital, clinics, and others.

    Asia Pacific would be the fastest-growing desmoid tumor market.

    The desmoid tumor market report includes players Novartis AG, Amgen Inc., Bayer AG, Abbott Laboratories, Beckman Coulter Inc., AbbVie Inc., Debiopharm Group, F. Hoffmann-La Roche Ltd, Stryker Corporation, and others.